The abstract is read at the publisher; the summary is JClub's.
In wound isolates of Pseudomonas aeruginosa from PhagoBurn trial participants treated with PP1131, 42% carried PP1131-derived phage genomes, including 39% with infectious chronic release.
- Why it matters: The PhagoBurn trial did not meet its primary endpoint, and this work addresses how overlooked non-lytic phage–bacterium interactions and adaptation may contribute to variable therapeutic outcomes.
- What they did: In a retrospective observational reverse-translational analysis in Switzerland, France, and Belgium, 184 isolates from seven individuals were phenotyped longitudinally for phage susceptibility, then 98 with unique profiles were genome sequenced.
- The result: Among 98 sequenced isolates, PP1131-derived phage genomes were detected in 41 (42%); 16 (39%) continuously released infectious phage, while 23 (56%) retained phage DNA without detectable release, stable after in vitro passages.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.